JAK Inhibitors for ET and PV: What Have We Learned So Far

JAK Inhibitors for ET and PV: What Have We Learned So Far

User Photo
HMP CME

3 years
673 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Ellen Ritchie discusses what we have learned thus far regarding the use of JAK inhibitors for the treatment of essential thrombocythemia (ET) and polycythemia vera (PV).

Earn accreditation for a related activity at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7221

© 2016 Imedex, LLC.
Up Next Autoplay